

Original Research

Fibrinogen-to-Albumin Ratio and Long-Term Mortality in Coronary Artery Disease Patients with Different Glucose Metabolism Status

Yun Xie^{1,2,3,†}, Xiayan Xu^{2,3,4,†}, Dongmei Wang^{5,†}, Yang Zhou^{2,3}, Yu Kang^{2,3,6},
Wenguang Lai^{1,2,3}, Hongyu Lu^{2,3}, Jin Liu^{2,3}, Shiqun Chen^{2,3}, Junyan Xu^{2,3}, Xiaoming Yan^{7,*},
Xiaoyu Huang^{8,*}, Yong Liu^{1,2,3,*}

¹School of Biology and Biological Engineering, South China University of Technology, 510006 Guangzhou, Guangdong, China

²Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China

³Department of Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China

⁴School of Medicine, South China University of Technology, 510006 Guangzhou, Guangdong, China

⁵Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Cadres Health Management Center, 510080 Guangzhou, Guangdong, China

⁶Shantou University Medical College, 515041 Shantou, Guangdong, China

⁷Department of Information Technology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China

⁸Department of Cardiology, Yangjiang People's Hospital, 529500 Yangjiang, Guangdong, China

*Correspondence: yanxiaoming@gdph.org.cn (Xiaoming Yan); 13302521912@189.cn (Xiaoyu Huang); liuyong@gdph.org.cn (Yong Liu)

†These authors contributed equally.

Academic Editors: Rajesh Katore and Gary David Lopaschuk

Submitted: 9 April 2023 Revised: 14 May 2023 Accepted: 31 May 2023 Published: 16 November 2023

Abstract

Background: Abnormal glucose metabolism is present in most patients with coronary artery disease (CAD). Inflammation is considered to be a common risk factor for CAD and diabetes. Fibrinogen-to-albumin ratio (FAR), a novel inflammation biomarker, has been proposed as a predictor for cardiovascular disease. However, the relationship between the level of FAR and long-term mortality including all-cause, cardiovascular and cancer mortality, remains unknown in CAD patients, especially those with prediabetes. **Methods:** We enrolled 66,761 CAD patients from 2007 to 2020 from a multi-center registry cohort study. The primary outcomes were the all-cause, cardiovascular and cancer mortality. FAR was calculated using the following formula: Fibrinogen (g/L)/Albumin (g/L). Patients were divided into three groups by FAR tertile (low FAR (FAR-L), median FAR (FAR-M), high FAR (FAR-H)), and further categorized into 9 groups according to FAR and glucose metabolism status (normal glucose regulation (NGR), prediabetes mellitus (PreDM), diabetes mellitus (DM)). Cox regression models and competing risk models were used to examine the relationships between FAR and clinical outcomes. **Results:** 66,761 patients (63.1 ± 11.0 years, 75.3% male) were enrolled. During the follow-up, 10,534 patients died, including 4991 cardiovascular deaths and 1092 cancer deaths. After adjusting for confounders, higher FAR was associated with increased risk of all-cause and cause-specific mortality in CAD patients with NGR, PreDM and DM. The risk of all-cause and cardiovascular mortality was highest in FAR-H with DM (HR (95% CI) = 1.71 (1.58–1.86), 2.11 (1.86–2.38), respectively; $p < 0.001$). FAR-H with PreDM was significantly associated with the highest risk of cancer mortality (HR (95% CI) = 2.27 (1.70–3.02), $p < 0.001$). Adding FAR to the original model significantly improved the prediction of long-term mortality. **Conclusions:** Increased FAR was significantly associated with higher risk of all-cause and cause-specific mortality in CAD patients with NGR, PreDM and DM. Abnormal glucose metabolism augments the relationship between FAR and mortality. **Clinical Trial Registration:** ClinicalTrials.gov NCT05050877.

Keywords: fibrinogen-to-albumin ratio; diabetes; prediabetes; long-term mortality; coronary artery disease

1. Introduction

Coronary artery disease (CAD) is identified as a major cause of death with more than 9 million deaths in 2019, accounting for 16% of all-cause deaths worldwide [1]. Despite the significant advancements in medical treatment, patients with CAD still face a substantial risk of death, which imposes immense health and economic burdens worldwide [2].

Abnormal glucose metabolism, including diabetes mellitus (DM) and prediabetes mellitus (PreDM), is present in most patients with CAD [3]. The 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases indicate that about 20–30% of patients with CAD have DM, and up to 70% of the remaining patients will be newly diagnosed with DM or PreDM [4]. Multiple epidemiological studies have confirmed that DM is one of the risk factors for CAD patients [5,6]. In addition, PreDM also increases the risk






Fig. 1. Flow of patients through the study. FAR, fibrinogen-to-albumin ratio; FAR-L, low FAR; FAR-M, median FAR; FAR-H, high FAR.

of adverse prognosis in CAD patients [7,8]. As a result, it is critical to pay closer attention to the glucose metabolism status of CAD patients in order to stratify their risk and better manage these risk factors for patients who are at high risk.

Inflammation is considered to be a common risk factor for CAD and diabetes [9,10]. A number of studies have shown that inflammatory markers have increased sensitivity for predicting the prognosis of both diabetes and CAD [11–14]. Fibrinogen (FIB), an inflammatory marker synthesized by the liver, as well as a coagulation factor involved in the formation of thrombosis and the progression of atherosclerosis, has been found to be closely related to the poor prognosis of CAD patients [15,16]. Albumin (ALB) is the most abundant plasma protein and has anti-inflammatory, antioxidant, and antithrombotic properties. Previous studies have indicated that low serum albumin concentration is associated with an increased risk of adverse cardiovascular events in CAD patients [17,18]. Fibrinogen-to-albumin ratio (FAR) is an innovative inflammatory biomarker that combines the above two indicators and has been widely used to predict adverse prognosis among patients with various cancers [19,20]. Recently, several studies have also confirmed that FAR is strongly linked to the severity of coronary lesions and poor clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease [21–

23]. However, the relationship between FAR, all-cause and cause-specific mortality is not fully understood in CAD patients with different glucose metabolism, especially those with prediabetes.

The purpose of this study was to investigate the potential relationship between FAR and long-term mortality among CAD patients, including all-cause, cardiovascular and cancer mortality, and further determine whether the association between FAR levels and clinical outcomes varies according to the glucose metabolism status, especially in those patients with prediabetes.

2. Materials and Methods

2.1 Study Population

This multi-center cohort study was based on the Cardiorenal Improvement II (CIN-II) study, which included patients recruited from 5 large tertiary hospitals in China between January 2007 and December 2020 (Cardiorenal Improvement II, ClinicalTrials.gov NCT05050877). We enrolled 66,761 CAD patients who underwent coronary angiography (CAG) at the time of initial admission. The exclusion criteria were as follows: (1) patients younger than eighteen years; (2) patients missing survival information; (3) patients without baseline plasma fibrinogen and plasma albumin data; (4) patients without baseline fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) (Fig. 1). This research was approved by the Ethics Com-

mittee of the Guangdong Provincial People's Hospital (No. GDREC2019-555H-2). To protect the privacy of patients, we removed all traceable personal identifiers from the database, and each participating site obtained institutional review board permission from the local ethics committees. Since this research involved retrospective cases, no additional intervention was necessary. Furthermore, the data we used has been desensitized and patient informed consent was not required. The study complied with the Declaration of Helsinki.

2.2 Baseline Data Collection

The baseline information including demographic characteristics, complications, procedures, laboratory examinations, and medications were obtained from the electronic clinical management system (ECMS). On initial admission, biochemistry data such as plasma fibrinogen, plasma albumin and HbA1c were obtained. Survival information was derived from a cause-specific surveillance dataset at the regional Center for Disease Control and Prevention (CDC).

2.3 Study Outcomes and Clinical Definition

The outcomes of this study were all-cause, cardiovascular and cancer mortality. FAR was defined as the ratio of fibrinogen (g/L) to albumin (g/L). According to the American Diabetes Association [24], DM was identified by FBG ≥ 7.0 mmol/L (126 mg/dL), or HbA1c $\geq 6.5\%$, or 2-h blood glucose of oral glucose tolerance test ≥ 11.1 mmol/L (200 mg/dL), or a previous diagnosis of DM with antidiabetic treatment. PreDM was diagnosed by $5.6 \text{ mmol/L} \leq \text{FBG} < 7.0 \text{ mmol/L}$ or $5.7\% \leq \text{HbA1c} < 6.5\%$. Normal glucose regulation (NGR) was defined as patients without PreDM or DM. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to calculate the estimated glomerular filtration rate (eGFR), and chronic kidney disease (CKD) was defined as $\text{eGFR} < 60 \text{ mL/min/1.73 m}^2$ [25,26]. Hyperlipemia, acute myocardial infarction (AMI) and hypertension (HT) were defined by using the 10th Revision Codes of the International Classification of Diseases (ICD-10) codes. Congestive heart failure (CHF) was defined as New York Heart Association class ≥ 3 or Killip class > 1 .

2.4 Statistical Analysis

According to the baseline FAR, patients were categorized into three groups: FAR-L, FAR-M, FAR-H, and further divided into nine groups according to FAR and glucose metabolism status (NGR, PreDM, DM). For the baseline characteristics, continuous variables were presented as mean with standard deviation (SD) or median with interquartile range (IQR) as appropriate. Categorical variables were described as counts and percentages. One-way ANOVA or the Kruskal–Wallis test was used for continuous variables. The χ^2 test was used for categorical variables.

In order to examine the correlation between FAR levels as a continuous variable and mortality for all-cause, cardiovascular, and cancer, we conducted restricted cubic splines (RCS) analyses. Kaplan-Meier survival curves were used to describe the time-to-event data, and differences were assessed using the log-rank tests. We evaluated the relationship between FAR and all-cause mortality by Cox regression models. FAR and cause-specific mortality were assessed by competing-risk models. Models were adjusted for the following covariates: age, gender, HT, CHF, AMI, CKD, stroke, hyperlipemia, respectively. A variance inflation factor ≥ 5 indicates the presence of multicollinearity between variables. The C-index was constructed to evaluate the change in the predictive accuracy of long-term mortality after the addition of FAR to the original clinical risk factors model (age, gender, HT, CHF, AMI, CKD, stroke, hyperlipemia). Correlations between HbA1c, FBG, FAR and its components were assessed using the Spearman correlation test. All data were analyzed using R version 4.0.3. (R Foundation for Statistical Computing, Vienna, Austria). A two-sided p value < 0.05 was considered statistically significant.

3. Results

3.1 Baseline Characteristics

A total of 66,761 patients with CAD (the mean age 63.1 ± 11.0 years, 75.3% were men) were enrolled in this study, including 21,982 patients with NGR, 20,723 with PreDM and 24,056 patients with DM. Based on the baseline FAR, the patients were categorized into 3 groups: FAR-L group ($n = 22,335$), FAR-M group ($n = 22,466$), FAR-H group ($n = 21,960$). The baseline characteristics between patients with different FAR are presented in Table 1. The FAR-M group had the highest proportion of females. From the FAR-L to the FAR-H group, patients with higher FAR were more likely to have HT, CHF, CKD, hyperlipemia and anemia. In addition, they had higher levels of eGFR, HbA1c, FIB, and lower levels of HGB, HDLC and ALB.

During a median follow-up of 4.68 years, 10,534 (15.8%) participants died, of which, 4991 (7.5%) were cardiovascular-specific deaths, and 1092 (1.6%) were cancer-specific deaths. For all-cause death or cause-specific death, the proportion of patients with a higher FAR was significantly higher than the FAR-L group (Table 1). A similar trend was also observed in patients with different glucose metabolism status (Table 2).

3.2 Different Glucose Metabolism Status, FAR, and Clinical Outcomes

RCS analysis demonstrated that the risk of all-cause or cause-specific death increased as FAR increased in CAD patients, but the relationship was not linear (all nonlinear $p < 0.001$) (Fig. 2). Kaplan-Meier curves indicated that the FAR-H group had the highest risk of all-cause mortality. The risk of cause-specific mortality also showed sim-

Table 1. Baseline characteristics based on FAR levels.

	Overall n = 66,761	FAR-L n = 22,335	FAR-M n = 22,466	FAR-H n = 21,960	p value
Demographic characteristics					
Age, years	63.1 (11.0)	61.4 (11.2)	63.7 (10.5)	64.5 (10.9)	<0.0001
Age >60, n (%)	40,666 (60.8)	12,361 (54.2)	14,437 (63.3)	13,823 (65.4)	<0.0001
Female, n (%)	16,514 (24.7)	5086 (22.3)	6239 (27.4)	5170 (24.4)	<0.0001
Complication					
Glucose metabolism status					<0.0001
NGR, n (%)	21,982 (32.9)	9439 (42.3)	6825 (30.4)	5715 (26.0)	
PreDM, n (%)	20,723 (31.0)	6117 (27.4)	7632 (34.0)	6970 (31.8)	
DM, n (%)	24,056 (36.0)	6779 (30.4)	8009 (35.6)	9262 (42.2)	
AMI, n (%)	15,788 (23.6)	4512 (19.8)	3809 (16.7)	7420 (35.1)	<0.0001
HT, n (%)	37,614 (56.3)	12,101 (53.1)	13,148 (57.6)	12,324 (58.3)	<0.0001
CHF, n (%)	9933 (14.9)	2423 (10.6)	2654 (11.6)	4835 (22.9)	<0.0001
CKD, n (%)	13,734 (20.5)	2757 (12.1)	4276 (18.7)	6689 (31.6)	<0.0001
AF, n (%)	3005 (4.5)	1060 (4.6)	967 (4.2)	975 (4.6)	0.068
Stroke, n (%)	4141 (6.2)	1240 (5.4)	1366 (6.0)	1531 (7.2)	<0.0001
Hyperlipemia, n (%)	43,135 (64.5)	13,524 (59.3)	14,483 (63.5)	15,078 (71.3)	<0.0001
Procedure					
PCI, n (%)	48,050 (71.9)	14,544 (63.8)	16,533 (72.5)	16,919 (80.0)	<0.0001
CABG, n (%)	104 (0.2)	24 (0.1)	38 (0.2)	42 (0.2)	0.0407
DES, n (%)	45,842 (68.6)	13,855 (60.8)	15,772 (69.2)	16,164 (76.4)	<0.0001
BMS, n (%)	1048 (1.6)	267 (1.2)	359 (1.6)	422 (2.0)	<0.0001
Laboratory tests					
eGFR, mL/min/1.73 m ²	78.5 (25.8)	84.2 (22.6)	79.3 (24.9)	71.6 (28.4)	<0.0001
HGB, g/L	133.5 (17.4)	138.0 (15.9)	134.4 (16.2)	127.7 (18.6)	<0.0001
SCr, mg/dL	1.0 [0.8, 1.1]	0.9 [0.8, 1.1]	0.9 [0.8, 1.1]	1.0 [0.8, 1.3]	<0.0001
LDLC, mmol/L	2.9 (1.0)	2.9 (1.1)	2.9 (1.0)	2.9 (1.0)	0.2722
HDLC, mmol/L	1.0 (0.3)	1.1 (0.3)	1.0 (0.3)	0.9 (0.3)	<0.0001
HbA1c, %	6.6 (1.4)	6.4 (1.3)	6.5 (1.3)	6.8 (1.6)	<0.0001
FIB, g/L	3.9 (1.3)	2.8 (0.4)	3.7 (0.4)	5.3 (1.1)	<0.0001
ALB, g/L	37.6 (4.5)	40.5 (3.7)	37.8 (3.3)	34.2 (4.1)	<0.0001
FAR	0.108 (0.045)	0.070 (0.010)	0.098 (0.008)	0.158 (0.044)	<0.0001
Medications					
Beta blocker, n (%)	51,171 (80.0)	16,657 (77.7)	17,722 (80.4)	16,733 (82.1)	<0.0001
Statins, n (%)	61,237 (95.8)	20,586 (96.0)	21,126 (95.9)	19,450 (95.4)	0.0047
CCB, n (%)	14,745 (23.1)	5395 (25.2)	5065 (23.0)	4261 (20.9)	<0.0001
ACEI/ARB, n (%)	44,850 (70.1)	14,386 (67.1)	15,763 (71.5)	14,651 (71.9)	<0.0001
Diuretics, n (%)	11,602 (18.1)	3112 (14.5)	3547 (16.1)	4929 (24.2)	<0.0001
Antiplatelet, n (%)	62,188 (97.3)	20,788 (97.0)	21,444 (97.3)	19,885 (97.5)	0.0016
Clinical Outcomes					
All-cause mortality, n (%)	10,534 (15.8)	2090 (9.4)	3237 (14.4)	5204 (23.7)	<0.0001
Cardiovascular mortality, n (%)	4991 (7.5)	833 (3.7)	1378 (6.1)	2779 (12.7)	<0.0001
Cancer mortality, n (%)	1092 (1.6)	193 (0.9)	365 (1.6)	533 (2.4)	<0.0001

Abbreviations: NGR, normal glucose regulation; PreDM, prediabetes mellitus; DM, diabetes mellitus; AMI, acute myocardial infarction; HT, hypertension; CHF, congestive heart failure; CKD, chronic kidney disease; AF, atrial fibrillation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; DES, drug eluting stent; BMS, bare metal stent; eGFR, estimated glomerular filtration rate; HGB, hemoglobin; SCr, serum creatinine; LDLC, low density lipoprotein cholesterol; HDLC, high density lipoprotein cholesterol; HbA1c, hemoglobin A1c; FIB, fibrinogen; ALB, albumin; FAR, fibrinogen-to-albumin ratio; CCB, calcium channel blocker; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; FAR-L, low FAR; FAR-M, median FAR; FAR-H, high FAR.

Table 2. Multivariable Cox regression models of the relationship between FAR and clinical outcomes in patients with different glucose metabolism.

FAR	All-cause mortality		Cardiovascular mortality		Cancer mortality	
	Events/subjects	HR (95% CI)	Events/subjects	HR (95% CI)	Events/subjects	HR (95% CI)
NGR	3125/21,982		1395/21,982		315/21,982	
FAR per-SD increase		1.12 (1.09–1.16) **		1.19 (1.14–1.25) **		1.22 (1.11–1.34) **
FAR-L	852/9439	Ref.	349/9439	Ref.	66/9439	Ref.
FAR-M	988/6825	1.18 (1.08–1.29) **	405/6825	1.15 (1.00–1.33)	111/6825	1.69 (1.25–2.28) **
FAR-H	1283/5715	1.35 (1.24–1.48) **	640/5715	1.47 (1.28–1.68) **	138/5715	2.02 (1.50–2.73) **
PreDM	3026/20,723		1238/20,723		386/20,723	
FAR per-SD increase		1.18 (1.14–1.21) **		1.23 (1.18–1.29) **		1.25 (1.14–1.36) **
FAR-L	552/6117	0.86 (0.78–0.96) *	179/6117	0.68 (0.57–0.81) **	62/6117	1.21 (0.87–1.70)
FAR-M	998/7632	0.99 (0.90–1.08)	381/7632	0.88 (0.76–1.02)	132/7632	1.61 (1.20–2.16) *
FAR-H	1476/6970	1.32 (1.21–1.44) **	678/6970	1.34 (1.17–1.53) **	192/6970	2.27 (1.70–3.02) **
DM	4383/24,056		2358/24,056		391/24,056	
FAR per-SD increase		1.21 (1.18–1.25) **		1.28 (1.24–1.33) **		1.25 (1.14–1.37) **
FAR-L	705/6029	1.01 (0.91–1.11)	314/6029	1.07 (0.92–1.25)	66/6029	1.24 (0.88–1.74)
FAR-M	1283/8167	1.21 (1.11–1.32) **	610/8167	1.29 (1.13–1.47) **	127/8167	1.59 (1.18–2.15) *
FAR-H	2395/8959	1.71 (1.58–1.86) **	1434/8959	2.11 (1.86–2.38) **	198/8959	2.20 (1.66–2.92) **

Adjusted for age, gender, hypertension, acute myocardial infarction, stroke, chronic kidney disease, hyperlipemia, congestive heart failure.

FAR, fibrinogen-to-albumin ratio; NGR, normal glucose regulation; PreDM, prediabetes mellitus; DM, diabetes mellitus; FAR-L, low FAR; FAR-M, median FAR; FAR-H, high FAR; HR, hazard ratio; CI, confidence interval; SD, standard deviation.

*, $p < 0.05$; **, $p < 0.001$.




Fig. 2. Restricted spline curve for the association between FAR and all-cause, cardiovascular, and cancer mortality based on multivariate Cox regression models. The multivariate Cox regression model includes adjustment for age, gender, hypertension, acute myocardial infarction, stroke, chronic kidney disease, hyperlipemia, and congestive heart failure. FAR, fibrinogen-to-albumin ratio; HR, hazard ratio.

ilar results (Fig. 3). In the FAR level as well as different glucose metabolism states, CAD patients were further classified into 9 groups. DM Patients in FAR-H had the highest risk of all-cause mortality and cardiovascular mortality, while the risk of cancer mortality was highest in FAR-H with PreDM (Fig. 4).

Table 2 shows three Cox regression models to further investigate the association among FAR, different glucose metabolism states and clinical outcomes. After adjusting for age, gender, HT, CKD, stroke, AMI, hyperlipemia,

CHF, the higher FAR group had a higher risk for all-cause and cause-specific mortality in NGR patients; similar results were found in the PreDM and DM groups. The risks of all-cause mortality (NGR, PreDM, DM: HR (95% CI) = 1.12 (1.09–1.16), 1.18 (1.14–1.21), 1.21 (1.18–1.25), respectively; all p values < 0.001), cardiovascular mortality (NGR, PreDM, DM: HR (95% CI) = 1.19 (1.14–1.25), 1.23 (1.18–1.29), 1.28 (1.24–1.33), respectively; all p values < 0.001) and cancer mortality (NGR, PreDM, DM: HR (95% CI) = 1.22 (1.11–1.34), 1.25 (1.14–1.36), 1.25 (1.14–1.37),




Fig. 3. Kaplan–Meier curves for all-cause, cardiovascular, and cancer mortality according to different FAR levels based on univariate Cox regression models. FAR, fibrinogen-to-albumin ratio; FAR-L, low FAR; FAR-M, median FAR; FAR-H, high FAR.




Fig. 4. Kaplan–Meier curves for all-cause, cardiovascular, and cancer mortality according to states of both FAR levels and glucose metabolism based on univariate Cox regression models. FAR, fibrinogen-to-albumin ratio; FAR-L, low FAR; FAR-M, median FAR; FAR-H, high FAR; NGR, normal glucose regulation; PreDM, prediabetes mellitus; DM, diabetes mellitus.

respectively; all p values < 0.001) elevated with per 1-SD increase in FAR. The risk increased with decreased levels of glucose metabolism (all p for trend < 0.001). In addition, FAR-H with DM group had the highest risk of all-cause and cardiovascular mortality (HR (95% CI) = 1.71 (1.58–1.86), HR (95% CI) = 2.11 (1.86–2.38), respectively; all p values < 0.001). FAR-H with PreDM group was significantly associated with the highest risk of cancer mortality (HR (95% CI) = 2.27 (1.70–3.02), p value < 0.001).

3.3 Risk Prediction for Clinical Outcomes with Different Glucose Metabolism Status

In order to determine whether FAR has an additional predictive value compared with the original model, we calculated the C-indexes with and without FAR. The original model included age, gender, HT, CHF, AMI, CKD, stroke and hyperlipemia. Regardless of all-cause or cause-specific

mortality, the addition of FAR to the model resulted in a significant improvement in C-indexes for NGR, PreDM and DM patients (all p value < 0.001) (Table 3).

3.4 Association between FAR and Glucose Metabolism

FAR showed a significantly positive correlation with glucose metabolism indexes including HbA1c ($r = 0.14$, $p < 0.001$) and FBG ($r = 0.10$, $p < 0.05$). **Supplementary Fig. 1** shows all correlations between HbA1c, FBG, FAR and its components.

4. Discussion

In this retrospective study, we demonstrated that elevated FAR was significantly related to a higher risk of all-cause, cardiovascular, and cancer mortality in CAD patients with different glucose metabolism status. Furthermore, abnormal glucose metabolism increases this association. In

Table 3. C-index of FAR for predicting clinical outcomes in subjects with different glucose metabolism status.

Model	All-cause mortality		Cardiovascular mortality		Cancer mortality	
	C-index	<i>p</i>	C-index	<i>p</i>	C-index	<i>p</i>
NGR original model	0.682 (0.670–0.694)		0.720 (0.704–0.736)		0.720 (0.693–0.747)	
NGR original model + FAR	0.687 (0.675–0.699)	<0.001	0.724 (0.708–0.74)	<0.001	0.733 (0.706–0.760)	<0.001
PreDM original model	0.673 (0.661–0.685)		0.748 (0.732–0.764)		0.701 (0.676–0.726)	
PreDM original model + FAR	0.683 (0.671–0.695)	<0.001	0.758 (0.742–0.774)	<0.001	0.721 (0.697–0.745)	<0.001
DM original model	0.691 (0.681–0.701)		0.734 (0.722–0.746)		0.685 (0.656–0.714)	
DM original model + FAR	0.701 (0.693–0.709)	<0.001	0.748 (0.736–0.760)	<0.001	0.700 (0.673–0.727)	<0.001

Original model included age, gender, hypertension, congestive heart failure, acute myocardial infarction, chronic kidney disease, stroke, hyperlipemia.

FAR, fibrinogen-to-albumin ratio; NGR, normal glucose regulation; PreDM, prediabetes mellitus; DM, diabetes mellitus.

addition, adding FAR to the original model enhanced the predictive power for long-term mortality. Our results indicate that FAR is an effective risk stratification tool for CAD patients with NGR, PreDM and DM.

Abnormal glucose metabolism is common in patients with CAD [4]. In a diabetes and heart survey involving 110 centers in Europe, up to 31% of patients with CAD were already known to have diabetes and 40% had newly discovered glucose abnormalities [3]. Hyperglycemia caused by insulin resistance induces mitochondrial dysfunction and endoplasmic reticulum stress, leading to endothelial dysfunction, ROS accumulation and inflammation, which ultimately contributes to the development of CAD [27,28]. Several epidemiological studies have also demonstrated that abnormal glucose metabolism was related to higher risk of adverse cardiovascular events and mortality among CAD patients. A large cohort study, including 3276 postinfarction patients, indicated that the occurrence of sudden cardiac death was higher in DM patients compared to non-DM patients [29]. Lenzen *et al.* [5] found that CAD patients with previously recognized and newly detected DM was associated with a 1.4- and 1-fold elevated risk of 1-year mortality, respectively, compared to those with NGR. The first Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction study also demonstrated an apparent beneficial effect of enhanced insulin-based glucometabolic control after AMI, which prolonged survival by 2.3 years [30]. Therefore, it is critical to monitor the glucose metabolism of CAD patients and intervene as soon as possible to improve the long-term prognosis of high-risk populations.

CAD and DM involve complex physiological processes, and chronic inflammation has been widely accepted as the pathological mechanism for these two diseases [9]. CAD is essentially an inflammatory disease, risk factors such as dyslipidemia, hyperglycemia, smoking, and hypertension induce endothelial cell damage, stimulate immune cell proliferation, resulting in the upregulate of the expression of inflammatory and procoagulant cytokines such as IL-1 β and FIB [31–34], ultimately leading to CAD. In diabetes, hyperglycemia and elevated free fatty acids can acti-

vate the JNK/IKK NF- κ B pathway and inflammatory cascade, which may trigger insulin resistance to exacerbate the development of diabetes and long-term complications [9,35,36]. Previous studies have showed that inflammation biomarkers can be used as an effective tool to predict the poor prognosis of CAD and DM patients. Higher FIB is independently linked to major adverse cardiovascular events in CAD patients, particularly in PreDM and DM [37]. The acute phase inflammatory biomarker albumin has also been found to be strongly associated with cardiovascular outcomes in CAD and DM patients [38–40]. Fibrinogen-to-albumin ratio (FAR), is a widely used novel inflammatory biomarker that has been shown outstanding capability in predicting the risk of poor clinical outcomes in patients with cancer and cardiovascular disease [41,42]. Nevertheless, the potential connection between FAR and long-term mortality among CAD patients with different glucose metabolism states, especially in those with PreDM, is not entirely understood. This research, for the first time demonstrates the relationship between FAR and long-term mortality in CAD patients with PreDM. We found that higher FAR levels in both NGR, PreDM and DM patients were significantly correlated with higher risks of all-cause and cause-specific mortality. In addition, the results of this study showed that abnormal glucose metabolism amplifies the relationship between FAR and mortality. The inflammatory state in diabetic patients increases the expression of IL-6 and TNF- α , and these cytokines increase the synthesis of FIB and the degradation of ALB, leading to the increased activation of the coagulation pathway and decreased antiplatelet capacity [17,43,44]. These changes will eventually result in the formation of thrombosis *in vivo*, which may be the potential pathophysiological mechanism responsible for this effect.

Several studies have found a strong connection between diabetes and cancer. Diabetes may stimulate the proliferation and metastasis of cancer cells and influence the development of tumors through various biological mechanisms, such as hyperinsulinemia, hyperglycemia or chronic inflammation [45]. Moreover, patients with diabetes have a higher cancer mortality compared with non-diabetic pa-

tients [46,47]. Therefore, this study also evaluated the predictive value of FAR for cancer death in CAD patients with different glucose metabolism states. Consistently, our research showed that PreDM and DM patients with FAR-H were significantly linked to higher risks of cancer mortality. However, the connection between FAR and cancer mortality in CAD patients classified by different glucose metabolism states is not fully understood. Therefore, additional research is required to clarify these potential connections.

In our study, elevated FAR was associated with increased long-term mortality in patients with CAD, and correlated with different glucose metabolism states. Abnormal glucose metabolism amplifies the relationship between FAR and death. Moreover, to the best of our knowledge, this study revealed the predictive effect of FAR on mortality risk in CAD patients with prediabetes, for the first time. On the basis of the correlation between FAR and mortality risk, monitoring FAR levels and controlling inflammation with several anti-inflammatory therapy may play an important role in decreasing mortality in high-risk groups. Further investigations will be necessary to prospectively verify the prediction power of FAR for all-cause, cardiovascular and cancer mortality among CAD patients with different glucose metabolism status.

This research has several limitations. First, this research was a retrospective observational analysis, which didn't reflect direct causation. Second, due to data limitations, the effect of the severity of coronary artery disease on the relationship between FAR and mortality was not analyzed. Third, we only assessed FAR levels at the time of admission. The dynamic changes of FAR were absent during follow-up. Fourth, despite the adjustment for potential confounding factors, possible confounders could not be fully adjusted. Fifth, this study only included CAD patients in China, and whether the findings of this study can be generalized to other populations remains unclear.

5. Conclusions

In conclusion, FAR is a valuable tool for risk stratification of CAD patients with NGR, PreDM, and DM. Increased levels of FAR were significantly associated with higher risks of all-cause and cause-specific mortality. Moreover, abnormal glucose metabolism amplifies the relationship between FAR and mortality. FAR levels can provide more precise risk stratification for high-risk CAD patients and provide essential information for improving the long-term prognosis of these patients.

Abbreviations

CAD, coronary artery disease; DM, diabetes mellitus; PreDM, prediabetes mellitus; NGR, normal glucose regulation; AMI, acute myocardial infarction; HT, hypertension; CHF, congestive heart failure; CKD, chronic kidney disease; AF, atrial fibrillation; PCI, percutaneous coro-

nary intervention; CABG, coronary artery bypass grafting; DES, drug eluting stent; BMS, bare metal stent; eGFR, estimated glomerular filtration rate; HGB, hemoglobin; SCr, serum creatinine; LDLC, low density lipoprotein cholesterol; HDLC, high density lipoprotein cholesterol; HbA1c, Hemoglobin A1c; FIB, fibrinogen; ALB, albumin; FAR, fibrinogen-to-albumin ratio; CCB, calcium channel blocker; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; FAR-L, low FAR; FAR-M, median FAR; FAR-H, high FAR.

Availability of Data and Materials

The datasets generated and analyzed during the current study are not publicly available due to the institution policy but are available from the corresponding author on reasonable request.

Author Contributions

The authors' responsibilities were as follows: (I) Research idea and study design: YX, XYX, DMW, YL. (II) Data acquisition: YX, XYX, WGL, JL, XMY. (III) Data analysis/interpretation: YX, YZ, HYL, SQC, JYX, XYH. (IV) Statistical analysis: YX, XYX, DMW, YK. (V) Supervision and mentorship: JL, SQC and JYX. (VI) Writing guidance: XMY, XYH and YL. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

The Ethics Committee of the Guangdong Provincial People's Hospital approved the study (No. GDREC2019-555H-2). All traceable personal identifiers were removed from the analytic dataset to protect patients' privacy and all participating sites received institutional review board approval from their own ethics committees. Our database is not open to the public since the privacy of the participants should be protected. Since our research included retrospective cases, there was no additional intervention, and information of all patients was desensitized, and no informed consent was required. It was conducted in accordance with the principles of the Declaration of Helsinki.

Acknowledgment

Not applicable.

Funding

This research was funded by Guangdong Provincial science and technology project (2020B111170011, DFJH2020026, DFJH201919); Guangdong Provincial science and technology project (KJ022021049); The National Science Foundation for Young Scientist of China (grant no.82070360). The funders had no role in the study design,

data collection, and analysis, decision to publish, or preparation of the manuscript; the work was not funded by any industry sponsors.

Conflict of Interest

The authors declare no conflict of interest.

Supplementary Material

Supplementary material associated with this article can be found, in the online version, at <https://doi.org/10.31083/j.rcm2411317>.

References

- [1] Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, *et al.* Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. *Journal of the American College of Cardiology*. 2020; 76: 2982–3021.
- [2] Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, *et al.* Heart disease and stroke statistics-2020 update: A report from the American Heart Association. *Circulation*. 2020; 141: e139–e596.
- [3] Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, *et al.* The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart. *European Heart Journal*. 2004; 25: 1880–1890.
- [4] Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, *et al.* 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal*. 2020; 41: 255–323.
- [5] Lenzen M, Rydén L, Ohrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W, *et al.* Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. *European Heart Journal*. 2006; 27: 2969–2974.
- [6] Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, *et al.* 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *European Heart Journal*. 2016; 37: 2315–2381.
- [7] Vistisen D, Witte DR, Brunner EJ, Kivimäki M, Tabák A, Jørgensen ME, *et al.* Risk of cardiovascular disease and death in individuals with prediabetes defined by different criteria: the Whitehall II study. *Diabetes Care*. 2018; 41: 899–906.
- [8] Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, *et al.* Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010; 375: 2215–2222.
- [9] Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. *Current Diabetes Reports*. 2013; 13: 435–444.
- [10] Jha JC, Ho F, Dan C, Jandeleit-Dahm K. A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. *Clinical Science*. 2018; 132: 1811–1836.
- [11] Sharif S, Van der Graaf Y, Cramer MJ, Kapelle LJ, de Borst GJ, Visseren FLJ, *et al.* Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. *Cardiovascular Diabetology*. 2021; 20: 220.
- [12] Yuan D, Jiang P, Zhu P, Jia S, Zhang C, Liu Y, *et al.* Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. *Cardiovascular Diabetology*. 2021; 20: 143.
- [13] He J, Bian X, Song C, Zhang R, Yuan S, Yin D, *et al.* High neutrophil to lymphocyte ratio with type 2 diabetes mellitus predicts poor prognosis in patients undergoing percutaneous coronary intervention: a large-scale cohort study. *Cardiovascular Diabetology*. 2022; 21: 156.
- [14] Jin YJ, An ZY, Sun ZX, Liu XC. NLRP3 Inflammasome as a Therapeutic Target for Atherosclerosis: A Focus on Potassium Outflow. *Reviews in Cardiovascular Medicine*. 2022; 23: 268.
- [15] Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniadis C, Stefanadis C. Fibrinogen and cardiovascular disease: genetics and biomarkers. *Blood Reviews*. 2011; 25: 239–245.
- [16] Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, *et al.* Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. *European Heart Journal*. 2006; 27: 2962–2968.
- [17] Manolis AA, Manolis TA, Melita H, Mikhailidis DP, Manolis AS. Low serum albumin: A neglected predictor in patients with cardiovascular disease. *European Journal of Internal Medicine*. 2022; 102: 24–39.
- [18] Chien SC, Chen CY, Leu HB, Su CH, Yin WH, Tseng WK, *et al.* Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. *International Journal of Cardiology*. 2017; 241: 1–5.
- [19] Li B, Deng H, Lei B, Chen L, Zhang X, Sha D. The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis. *Frontiers in Oncology*. 2022; 12: 985377.
- [20] Wen Y, Yang J, Han X. Fibrinogen-to-Albumin Ratio is Associated with All-Cause Mortality in Cancer Patients. *International Journal of General Medicine*. 2021; 14: 4867–4875.
- [21] Duan Z, Luo C, Fu B, Han D. Association between fibrinogen-to-albumin ratio and the presence and severity of coronary artery disease in patients with acute coronary syndrome. *BMC Cardiovascular Disorders*. 2021; 21: 588.
- [22] Zhang DP, Mao XF, Wu TT, Chen Y, Hou XG, Yang Y, *et al.* The fibrinogen-to-albumin ratio is associated with outcomes in patients with coronary artery disease who underwent percutaneous coronary intervention. *Clinical and Applied Thrombosis/Hemostasis*. 2020; 26: 1076029620933008.
- [23] Liu G, Fan CM, Guo H, Fan WN, Li ML, Cui GX. Fibrinogen-to-albumin ratio predicts long-term outcomes for patients with ST-elevation myocardial infarction and multivessel disease: A prospective observational cohort study. *Experimental and Therapeutic Medicine*. 2021; 21: 465.
- [24] American Diabetes Association. 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes-2020*. *Diabetes Care*. 2020; 43: S14–S31.
- [25] Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Annals of Internal Medicine*. 1999; 130: 461–470.
- [26] Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, *et al.* Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney International*. 2005; 67: 2089–2100.
- [27] Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development

- of cardiovascular disease. *Cardiovascular Diabetology*. 2018; 17: 122.
- [28] Fiorentino TV, Prioleta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. *Current Pharmaceutical Design*. 2013; 19: 5695–5703.
- [29] Junttila MJ, Barthel P, Myerburg RJ, Mäkitallio TH, Bauer A, Ulm K, *et al.* Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. *Heart Rhythm*. 2010; 7: 1396–1403.
- [30] Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. *The Lancet Diabetes and Endocrinology*. 2014; 2: 627–633.
- [31] Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. *Heart*. 2006; 92: 441–444.
- [32] Randolph GJ. Mechanisms that regulate macrophage burden in atherosclerosis. *Circulation Research*. 2014; 114: 1757–1771.
- [33] Libby P. interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. *Journal of the American College of Cardiology*. 2017; 70: 2278–2289.
- [34] Lowe GDO. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. *Journal of Thrombosis and Haemostasis*. 2005; 3: 1618–1627.
- [35] Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. *Diabetes Care*. 2016; 39: S244–S252.
- [36] Shulman GI. Cellular mechanisms of insulin resistance. *The Journal of Clinical Investigation*. 2000; 106: 171–176.
- [37] Liu SL, Wu NQ, Shi HW, Dong Q, Dong QT, Gao Y, *et al.* Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. *Cardiovascular Diabetology*. 2020; 19: 36.
- [38] Ronit A, Kirkegaard-Klitbo DM, Dohmann TL, Lundgren J, Sabin CA, Phillips AN, *et al.* Plasma albumin and incident cardiovascular disease: results from the CGPS and an updated meta-analysis. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2020; 40: 473–482.
- [39] Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *Journal of the American Medical Association*. 1998; 279: 1477–1482.
- [40] Cano-Megías M, Bouarich H, Guisado-Vasco P, Pérez Fernández M, de Arriba-de la Fuente G, Álvarez-Sanz C, *et al.* Coronary artery calcification in patients with diabetes mellitus and advanced chronic kidney disease. *Endocrinología, Diabetes y Nutrición*. 2019; 66: 297–304.
- [41] Fang L, Yan FH, Liu C, Chen J, Wang D, Zhang CH, *et al.* Systemic inflammatory biomarkers, especially fibrinogen to albumin ratio, predict prognosis in patients with pancreatic cancer. *Cancer Research and Treatment*. 2021; 53: 131–139.
- [42] Huang R, Dai Q, Chang L, Wang Z, Chen J, Gu R, *et al.* The association between fibrinogen-to-albumin ratio (FAR) and adverse prognosis in patients with acute decompensated heart failure at different glucose metabolic states. *Cardiovascular Diabetology*. 2022; 21: 241.
- [43] Ceriello A. Fibrinogen and diabetes mellitus: is it time for intervention trials? *Diabetologia*. 1997; 40: 731–734.
- [44] Dunn EJ, Ariëns RAS. Fibrinogen and fibrin clot structure in diabetes. *Herz*. 2004; 29: 470–479.
- [45] Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, *et al.* Diabetes and cancer: a consensus report. *Diabetes Care*. 2010; 33: 1674–1685.
- [46] Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. *Diabetes Care*. 2012; 35: 1835–1844.
- [47] Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, *et al.* Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. *Journal of the American Medical Association*. 2008; 300: 2754–2764.